Related Experiment Video
Updated: Jan 9, 2026
Minimally Invasive Treatment for Thoracolumbar Burst Fracture Using Sagittal Alignment Screws and A Trauma Reduction Device
Published on: November 8, 2024
Vertebral changes evaluated by hounsfield units after spinal fusion surgery with concomitant anabolic therapy
Ayako Tominaga1,2, Keiji Wada3,4, Ken Okazaki1
1Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
None:
We analyzed vertebral changes in spinal fusion patients treated with teriparatide or romosozumab. Both therapies improved bone quality, but romosozumab showed a significantly greater HU increase. These findings suggest that romosozumab demonstrated a more pronounced effect than TPD in patients undergoing spinal fusion surgery.
Purpose:
Osteoporosis negatively impacts spinal fusion surgery outcomes. Although teriparatide (TPD) has been used perioperatively, romosozumab (ROMO) has recently gained attention. This study aimed to evaluate changes in vertebral bone density using computed tomography (CT)-derived Hounsfield units (HU) before and after spinal fusion surgery and to examine the impact of concomitant bone anabolic therapy.
Methods:
This is retrospective cohort study included 115 patients who underwent spinal fusion surgery between 2021 and 2023. Patients were categorized into three groups: non-osteoporosis, teriparatide-treated, and romosozumab-treated (n = 27, each). Osteoporosis therapy was initiated 59.5 days preoperatively and continued postoperatively. HU values were assessed at the levels of one and two vertebrae above the uppermost instrumented level (HU + 1, HU + 2) at two time points: preoperatively and 12 months postoperatively. The primary outcome measure was the percent change of HU values over time.
Results:
The non-osteoporosis group exhibited no significant changes in HU values 12 months postoperatively. Both the TPD and ROMO groups demonstrated significant increases in the percent change of HU values from baseline to 12 months postoperatively. Moreover, the ROMO group exhibited a significantly greater increase in the percent change of HU values than the non-osteoporosis and TPD groups at HU + 1. (p < 0.001 and p < 0.009, respectively).
Conclusion:
Perioperative administration of TPD and ROMO significantly improved vertebral bone density, as determined by HU values. ROMO demonstrated a more pronounced effect than TPD, suggesting that it may be the preferred option for optimizing bone density in patients undergoing spinal fusion surgery.
